[go: up one dir, main page]

MX2023006842A - Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. - Google Patents

Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.

Info

Publication number
MX2023006842A
MX2023006842A MX2023006842A MX2023006842A MX2023006842A MX 2023006842 A MX2023006842 A MX 2023006842A MX 2023006842 A MX2023006842 A MX 2023006842A MX 2023006842 A MX2023006842 A MX 2023006842A MX 2023006842 A MX2023006842 A MX 2023006842A
Authority
MX
Mexico
Prior art keywords
pyrrolo
intermediates
manufacturing process
pyrimidine compound
crystalline form
Prior art date
Application number
MX2023006842A
Other languages
English (en)
Inventor
Kris Nicole Jones
Kapildev Kashmirilal Arora
Jacob Cole Deforest
Andrew Kevern Hills
Brian Patrick Jones
Chad Arthur Lewis
Anil Mahadeo Rane
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2023006842A publication Critical patent/MX2023006842A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un proceso de fabricación de intermediarios para preparar una forma cristalina o no cristalina de N-((1S,3S)-3-(metil(7H-pirrolo [2,3-d]pirimidin-4-il)amino)ciclobutil)propan-1-sulfonamida; formas de sal y composiciones farmacéuticas que comprenden la forma cristalina, y métodos para el uso del compuesto preparado de una forma cristalina en el tratamiento de diversas enfermedades.
MX2023006842A 2018-07-06 2020-12-16 Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. MX2023006842A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862694698P 2018-07-06 2018-07-06
US201862776642P 2018-12-07 2018-12-07
US201962855071P 2019-05-31 2019-05-31

Publications (1)

Publication Number Publication Date
MX2023006842A true MX2023006842A (es) 2023-06-22

Family

ID=67928862

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020013896A MX2020013896A (es) 2018-07-06 2019-07-03 Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.
MX2023006842A MX2023006842A (es) 2018-07-06 2020-12-16 Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020013896A MX2020013896A (es) 2018-07-06 2019-07-03 Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.

Country Status (15)

Country Link
US (3) US10815240B2 (es)
EP (1) EP3817810B1 (es)
JP (1) JP7437646B2 (es)
KR (1) KR102568464B1 (es)
CN (1) CN112384282B (es)
AU (1) AU2019299666B2 (es)
BR (1) BR112020025701A2 (es)
CA (1) CA3105161C (es)
ES (1) ES3045115T3 (es)
HR (1) HRP20251339T1 (es)
IL (1) IL279926B2 (es)
MX (2) MX2020013896A (es)
TW (1) TWI709562B (es)
WO (1) WO2020008391A1 (es)
ZA (1) ZA202100196B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232470A1 (en) 2019-05-13 2020-11-19 Boragen, Inc. Chemical compounds
CN113637018A (zh) 2020-04-27 2021-11-12 苏州晶云药物科技股份有限公司 磺酰胺类化合物的晶型及其制备方法
CN112279785B (zh) * 2020-10-29 2022-08-16 苏利制药科技江阴有限公司 3,3-二氟环丁胺盐酸盐中间体及其合成方法和3,3-二氟环丁胺盐酸盐合成方法
CN113583992B (zh) * 2021-07-15 2023-06-27 华东理工大学 一种还原胺化酶及其在仲胺合成中的应用
WO2023036289A1 (zh) * 2021-09-10 2023-03-16 上海海和药物研究开发股份有限公司 具有enpp1抑制活性的异羟基肟酸类化合物及其用途
ES2993658B2 (es) 2023-06-27 2025-07-02 Moehs Iberica Sl (3-(metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino)ciclobutilo)carbamato de bencilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de abrocitinib
ES3040374A1 (es) * 2024-04-30 2025-10-30 Moehs Iberica Sl Cocristales de N-{cis-3-[metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino]ciclobutil}propano-1-sulfonamida

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP4126781B2 (ja) 1998-10-26 2008-07-30 宇部興産株式会社 １−スルホニルピラゾール誘導体及びその製造方法
JP2003005323A (ja) 2001-06-20 2003-01-08 Konica Corp 熱現像写真感光材料及び画像形成方法
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
SG177645A1 (en) 2009-08-10 2012-02-28 Bellus Health Inc Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid
AR087072A1 (es) 2011-07-08 2014-02-12 Syngenta Participations Ag Procesos para la preparacion de tietanamina
MA38347A1 (fr) 2013-02-22 2017-10-31 Pfizer Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
EP3180344B1 (en) 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase

Also Published As

Publication number Publication date
CN112384282A (zh) 2021-02-19
TW202017929A (zh) 2020-05-16
EP3817810C0 (en) 2025-09-17
US20210009601A1 (en) 2021-01-14
CN112384282B (zh) 2024-07-02
KR20210029234A (ko) 2021-03-15
US20200123159A1 (en) 2020-04-23
CA3105161A1 (en) 2020-01-09
WO2020008391A1 (en) 2020-01-09
IL279926B2 (en) 2023-12-01
TWI709562B (zh) 2020-11-11
KR102568464B1 (ko) 2023-08-21
EP3817810B1 (en) 2025-09-17
HRP20251339T1 (hr) 2025-12-19
IL279926A (en) 2021-03-01
US20220127274A1 (en) 2022-04-28
JP2020007308A (ja) 2020-01-16
AU2019299666A1 (en) 2021-01-07
US12018031B2 (en) 2024-06-25
BR112020025701A2 (pt) 2021-03-16
AU2019299666B2 (en) 2024-07-11
US10815240B2 (en) 2020-10-27
ES3045115T3 (en) 2025-11-27
CA3105161C (en) 2022-11-15
JP7437646B2 (ja) 2024-02-26
IL279926B1 (en) 2023-08-01
EP3817810A1 (en) 2021-05-12
MX2020013896A (es) 2021-03-09
ZA202100196B (en) 2022-09-28
US11254684B2 (en) 2022-02-22

Similar Documents

Publication Publication Date Title
MX2023006842A (es) Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.
MX387902B (es) PROCESO PARA LA PREPARACION DE PIRAZOLO[1,5-a]PIRIMIDINAS Y SALES DE ESTAS.
MX2021003241A (es) Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo.
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
PH12018500437A1 (en) Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
TNSN06226A1 (en) Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
NZ604345A (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
MY150059A (en) Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
MX370390B (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
UA93375C2 (ru) Ингибиторы протеинкиназ ha ochobe замещенных амидов
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
GEP20217327B (en) Spirocycle compounds and methods of making and using same
PH12021552533A1 (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
MX2021002042A (es) Inhibidores de arginasa y sus metodos de uso.
EA202190323A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk
EP4295916A3 (en) Salts of 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and crystalline forms thereof
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
EA201990364A1 (ru) КРИСТАЛЛИЧЕСКИЕ И СОЛЕВЫЕ ФОРМЫ 7-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И СПОСОБ ИХ ПОЛУЧЕНИЯ
MX2018009912A (es) Proceso para preparar compuestos de 7h-pirrolo[2,3-d]pirimidina.
MX2020013847A (es) Forma cristalina del compuesto para inhibir la actividad de cdk4/6 y uso del mismo.